Onyx Pharmaceuticals (ONXX) ruffled some feathers last week by announcing a fundraising effort to raise around $300m, prompting shareholders to fret about what the already cash-rich company has planned. Vague talk about licensing opportunities by man...
Onyx Pharmaceuticals (ONXX) ruffled some feathers last week by announcing a fundraising effort to raise around $300m, prompting shareholders to fret about what the already cash-rich company has planned. Vague talk about licensing opportunities by man...
Last Wednesday Onyx Pharmaceuticals (ONXX) announced that it was going to raise additional financing by selling as much as 4.6 million shares and $230mm in convertible notes. The euphoria from the company s recent successful Phase 2 breast cancer ...
After releasing promising data from a mid-stage trial of regorafenib in kidney cancer, the company came out with impressive data on Nexavar for the treatment of breast cancer. Nexavar, which Bayer (BAYRY.PK) co-developed with Onyx Pharmaceuticals (ON...
After releasing promising data from a mid-stage trial of regorafenib in kidney cancer, the company came out with impressive data on Nexavar for the treatment of breast cancer. Nexavar, which Bayer (BAYRY.PK) co-developed with Onyx Pharmaceuticals (ON...
After releasing promising data from a mid-stage trial of regorafenib in kidney cancer, the company came out with impressive data on Nexavar for the treatment of breast cancer. Nexavar, which Bayer (BAYRY.PK) co-developed with Onyx Pharmaceuticals (ON...
After releasing promising data from a mid-stage trial of regorafenib in kidney cancer, the company came out with impressive data on Nexavar for the treatment of breast cancer. Nexavar, which Bayer (BAYRY.PK) co-developed with Onyx Pharmaceuticals (ON...
Onyx s (ONXX) stock decline in the past few months puzzled its shareholders. Nothing that has come in the news in the past year has been bad. On the contrary, a string of promising results was incessantly coming from the clinical trials of the firm...
Onyx s (ONXX) stock decline in the past few months puzzled its shareholders. Nothing that has come in the news in the past year has been bad. On the contrary, a string of promising results was incessantly coming from the clinical trials of the firm...
Onyx s (ONXX) stock decline in the past few months puzzled its shareholders. Nothing that has come in the news in the past year has been bad. On the contrary, a string of promising results was incessantly coming from the clinical trials of the firm...
Jeff Matthews Is Not Making This Up The World of Wall Street in all its glory, and anything else that strikes our fancy. Informed observations about comp...
Stock Market Beat Our beat is the stock market. Our job is to beat it....
TechCrunch TechCrunch profiles the companies, products and events that are defining and transforming the new web. TechCrunch is ...
Trader Mike Stock market commentary & trading ideas. Stock market weblog (blog), swing trading, day trading, stock picks, techni...
.gif)
Environmental Economics
Paul Kedrosky's Infectious Greed
Jeff Matthews Is Not Making This Up
TechCrunch
Trader Mike